The coronavirus disease 2019 (COVID-19) pandemic, caused by infection with the severe
acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is having a deleterious impact on …

Despite mass public health efforts, the SARS-CoV2 pandemic continues as of late 2021 with
resurgent case numbers in many parts of the world. The emergence of SARS-CoV2 variants …

RNA vaccines have demonstrated efficacy against SARS-CoV-2 in humans, and the
technology is being leveraged for rapid emergency response. In this report, we assessed …

A self-transcribing and replicating RNA (STARR)-based vaccine (LUNAR-COV19) has been
developed to prevent SARS-CoV-2 infection. The vaccine encodes an alphavirus-based …

The spread of the SARS-CoV-2 into a global pandemic within a few months of onset
motivates the development of a rapidly scalable vaccine. Here, we present a self-amplifying …

SARS-CoV-2 infection has emerged as a serious global pandemic. Because of the high
transmissibility of the virus and the high rate of morbidity and mortality associated with …

Messenger RNA (mRNA) vaccine technology has shown its power in preventing the
ongoing COVID-19 pandemic. Two mRNA vaccines targeting the full-length S protein of …

There is an urgent need for vaccines against coronavirus disease 2019 (COVID-19)
because of the ongoing SARS-CoV-2 pandemic. Among all approaches, a messenger RNA …

To successfully protect against pathogen infection, a vaccine must elicit efficient adaptive
immunity, including B and T cell responses. While B cell responses are key, as they can …

Abstract mRNA technologies have recently proven clinical efficacy against coronavirus
disease 2019 and are among the most promising technologies to address the current …